In his current role as a Senior Business Development Manager at Yoh Life Sciences, Diego leverages his extensive knowledge to drive workforce solutions for scientific and clinical companies. His responsibilities encompass managing Salesforce and Bullhorn tracking systems, cultivating connections through various communication channels, and overseeing client relationships across Northern and Southern California. His previous experience as a Business Development Manager at Piramal Pharma Solutions saw him break into the Latin American market, generating multimillion-dollar business and collaborating with technical and project management teams to ensure seamless project execution.Diego’s scientific expertise is deeply rooted in stem cell biology. He has significant experience in cGMP manufacturing of allogeneic stem cells for treating inflammatory disorders and lentiviral transduction in neuro stem cells. His work with mRNA IVT and transfection for iPSC transition highlights his proficiency in cutting-edge techniques aimed at reversing aging in various cell phenotypes. His hands-on skills include primary cell harvesting, cell culture, and working with a diverse array of phenotypes such as monocytes, macrophages, HEK293, keratinocytes, hematopoietic stem cells, mesenchymal stem cells, and neuro stem cells. He is also adept in advanced methodologies like vector engineering, ligation, PCR, qPCR, FACS, ELISA, histone extraction, and fluorescence microscopy.

Diego’s career has been marked by significant achievements, including the development of a mesenchymal stem cell product from cord tissue for private banking and managing lab operations at Turn Biotechnologies as the first employee. At Invitrx Therapeutics, he served as a Senior Application Scientist, where he provided technical support to sales and marketing teams and manufactured cord blood and birth tissue under stringent cGMP conditions.

Diego’s diverse experience and robust skill set make him a highly valuable asset in the fields of stem cell research and business development, continually driving innovation and excellence in his endeavors.

Asa serves as a principal investigator, consultant, medical director, and subject matter expert for INDs, IRBs, ATMPs, Clinical Trials in Regenerative Medicine Therapies and Devices, Global Regulatory Compliance, International Quality Management Systems, cGMP, cGLP, cGTP compliance, Gap Audits, Internal and External Audits, Supplier Evaluations, and successfully executing projects internationally. She excels in evaluating technologies, managing technology transfer, conducting risk assessments and management, obtaining Accreditations and Certifications (AABB, AATB, FACT, JCI, CAP, ISO, US FDA, DCGI, MOHAP, and global regulations), and conducting Training and Medical Education as a Subject Matter Expert.Among her career highlights, Asa has been a member of CTSCC (Cell Therapy Subsection Coordinating Committee), International Variance Committee, Quality, Cord Blood Banking, at AABB (American Association of Blood Banks) representing global experts for Cell and Gene Therapy. She has also been an international-ambassador of AABB for Cellular Therapies (Cell, Tissue, and Gene) since 2015, an advisor to Parents guide to cord blood foundation, Maryland, USA, since 2014, an advisor to Regenerative Outcomes, LLC, Nashville, TN, USA since 2018, and an International Faculty for the Stem Cell Group of India (for regulations and advocacy of stem cells in India).

Asa has been instrumental in laying down Cord Blood banking and Stem Cell Banking regulations in India associated with DCGI, ICMR India, and serves as a consultant for DHCR (Dubai Healthcare City), Dubai Health authority, Ministry of Health, UAE. She is a sought-after speaker, moderator, committee member at international conferences and meetings, and has international publications in Journals of significance. As a Medical Consultant, she provides expertise to Biotech, Pharmaceutical, and Regenerative Medicine Facilities and Companies Globally.

She serves as Chair of Standards Evaluation for International Variance, Co-chair Asia Pacific group and Quality and Regulatory Management, member of Regulatory Affairs Committee that Liaisons with FDA, EU and other regulatory bodies around the world.

In March 2023, Dr. Faulkner launched Castle Rock Regenerative Healthcare, where he offers concierge internal medicine services, including bio-identical hormone replacement and stem cell therapy. His practice also addresses weight loss with semaglutide and tirzepatide. Dr. Faulkner is a frequent guest and fill-in host on 560 KLZ’s “Rush to Reason,” where he discusses medical topics such as stem cell therapy and bio-identical hormone replacement. Additionally, he serves on the Scientific and Medical Board of Advisors for Cord For Life, contributing his expertise to the field.Dr. Faulkner’s extensive background includes roles as a hospitalist for Rural Physicians Group, where he has provided locum tenens services to multiple hospitals across Colorado and Arizona since 2010. His previous experience includes a position with Centura Health Physicians Group and a fee-for-service role at the Grand Junction VA Hospital.

His earlier career highlights include ownership of the Fort Morgan Sleep Disorder Center and a solo practice at Fort Morgan Internal Medicine Center. He has also held significant positions, such as Chief of Internal Medicine/Cardiopulmonary at MacDill Air Force Base, where he led a team and implemented key improvements in patient care and operational efficiency.

Dr. Faulkner’s educational background includes degrees from American University of the Caribbean and University of Northern Colorado, with further training at Berkshire Medical Center and Loma Linda University. He holds certifications in Advanced Cardiac Life Support and Basic Life Support and is board-certified by the American Board of Internal Medicine. His current practice is based in Larkspur, Colorado.

Dr. Irrgang completed her Pathology residency at Baylor University Medical Center and her internship at the University District Hospital, Rio Piedras in San Juan, Puerto Rico. Currently, she is Board Certified in Anatomic and Clinical Pathology and licensed in South Carolina, Texas, New Jersey, and Florida. Dr. Irrgang serves as an Associate Medical Examiner at the District Nine Medical Examiners Office and is a fellow of several organizations, including The College of American Pathologists, National Association of Medical Examiners, Florida Association of Medical Examiners, Seminole County Medical Society, and the Florida Medical Society. She has a passion for breeding show horses and is a 4-H leader in Lake County, Florida.

Kevin Kong is also a successful biotech investor, with notable returns such as Turning Point Therapeutics (20x return), and has operated and owned healthcare services companies like Rosewood Rehab.With a background in Oncology Research from the University of California, Kevin holds a PharmD from the University of the Pacific, graduating at the age of 21. His expertise lies in Clinical Development, Regulatory Affairs, and Business Development within the Healthcare, Biotechnology, and Cosmetics industries.

Attention to detail and a profound understanding of how the body moves and functions over time enables Dr. Naidoo to help his patients heal from their injuries, improve their quality of life and return to a lifestyle they once enjoyed.Dr. Naidoo collaborates with cutting edge pharmaceutical companies focused on cellular and regenerative medicine as a consultant and also served as Chief Medical Officer of several companies.

Dr. Naidoo is an invited lecturer on cellular therapy at prestigious academic institutions worldwide and educates physicians on cellular therapy as well as host an international scientific Cellular Therapy Conference annually.

After a career teaching orthopedic surgery in NYC at Mt Sinai School of Medicine, Dr. Naidoo relocated to Florida and established an orthopedic concierge practice in Palm Beach at which location he takes care of US an international patients with clinics and research labs in Hong Kong, Dubai and Abudhabi. Dr. Naidoo maintains an active Research collaboration at Harvard University at the Dean center for Tick Borne diseases. Dr. Naidoo is the Global Chief Medical officer of World Biotech Inc. in Hong Kong and Integrative Medical Health and Wellness Clinics, USA.

Dr. Naidoo is a native of South Africa and in his early years proudly served the revolutionary army of Nelson Mandela in South Africa’s struggle for Freedom.

Dr. Bojjireddy is currently serving as the Associate Vice President of R&D at Turn Biotechnologies, where he oversees research and development activities, manages budgets and timelines, and plays a pivotal role in company strategy and fund raising. He is involved in evaluating and partnering with companies in the mRNA and lipid nanoparticle (LNP) sectors, and leads a multidisciplinary R&D team in developing cutting-edge technologies. His contributions also include due diligence for potential acquisitions and patent filings.

Previously, as Sr. Director and Director of R&D at Turn Biotechnologies, Dr. Bojjireddy developed mRNA platforms for therapeutic applications and engineered plasmid vectors for mRNA production. His work also involved developing novel technologies for reprogramming aged cells and creating induced pluripotent stem cell (iPSC) lines to address aging issues.

At IGeneX Inc, Dr. Bojjireddy managed a team working on CRISPR-based stable cell lines and hybridoma generation, and led the development of multiplex qPCR assays for detecting diseases like Lyme disease. His earlier roles included significant contributions to protein expression, purification, and the development of immunoassays.

Dr. Bojjireddy’s academic background includes a Ph.D. in Immunology & Molecular Biology from the Indian Institute of Technology, Bombay. His research at institutions like the University of Washington and the National Institutes of Health focused on understanding cellular mechanisms and developing high-throughput assays. His notable work includes creating stable cell lines with CRISPR and developing non-radioactive assays for enzyme screening.

He holds several patents related to synthetic RNA constructs, polycistronic vectors, and immune cell rejuvenation technologies, reflecting his innovative approach in stem cell and molecular biology research.

Dr. Bojjireddy’s technical expertise spans molecular biology, immunology, cell culture, and biochemistry, making him a highly skilled professional in the development of advanced biotechnological solutions.

Dr. Senapathi is currently leading Senapathi Biologicx Medicine (SBM), which he founded in December 2017 in Makassar, South Sulawesi, Indonesia. Under his leadership, SBM focuses on the development of Good Laboratory Practices (GLPs) and biopharmaceuticals, with an emphasis on advancing cellular therapies within Indonesia.

In addition to SBM, Dr. Senapathi founded and serves as President of Senapathi Biologicx Pvt Ltd in Chennai, India, starting in December 2015. This company specializes in the production and research of human umbilical cord blood and cord tissue stem cells, aiming to develop cellular therapies for neurodegenerative diseases and Chronic Obstructive Pulmonary Disease (COPD).

From July 2003, Dr. Senapathi has held the role of Vice President at Pathogenesys, overseeing GLPs and biopharmaceuticals development and compliance. His previous experience includes a notable tenure at Allergan Gene Toxicology in Irvine, California, where he provided regulatory expertise and ISO 13485 guidance for over 90 scientists from May 2005 to June 2008. His work included conducting Micronucleus assays and AMES testing.

Before this, Dr. Senapathi was the Director of Quality Control at Meyer Pharmaceuticals in Irvine, California, from January 1998 to July 2002. In this role, he managed immunotherapy product testing and was an expert in flow cytometry and surrogate multiple lymphocyte culture testing for cytokines and cell surface markers.

Dr. Senapathi began his career as a Staff Research Associate at the University of California, Irvine – College of Medicine, where he conducted significant research in the Department of Pathology from March 1991 to December 1997. His research included cell signaling, tumor immunology, cancer stem cells, and involved the production and testing of pancreatic carcinoma intratumor immunotherapy implants.

Dr. Senapathi holds a PhD in Biology and Philosophy from the University of Madras (1975–1985) and has furthered his expertise through a Management Certificate program in Medical Devices Risk Management at Virginia Tech (2005–2006) and a Patient Care Special Course at UC Irvine (1994–1995). He is an active member of AHP and RAPS.

With a robust skill set in Good Laboratory Practices, Clinical Research, Biotechnology, Oncology, and more, Dr. Senapathi is a distinguished leader in his field.